Kymriah

Tisagenlecleucel, the active ingredient in Kymriah, is a CAR‑T cell therapy presented as an infusion for intravenous use. It treats relapsed or refractory B‑cell acute lymphoblastic leukemia in patients up to 25 years of age and relapsed or refractory diffuse large B‑cell lymphoma in adults.

GNH USA supplies Kymriah as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant centres, pharmacies and clinics worldwide.

Kymriah is indicated for CD19‑positive B‑cell malignancies that have relapsed or are refractory to standard therapy.

- Relapsed or refractory B‑cell acute lymphoblastic leukemia (ALL) in patients up to 25 years: provides targeted cellular therapy to achieve remission. - Relapsed or refractory diffuse large B‑cell lymphoma (DLBCL) in adults: offers a CAR‑T option when conventional treatments have failed. - Other CD19‑positive B‑cell lymphomas: delivers autologous CAR‑T cells to induce tumor cell lysis.

Kymriah may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Cytokine release syndrome (fever, hypotension, tachycardia, and flu‑like symptoms) - Neurologic toxicities (headache, confusion, tremor, or mild seizures) - Fatigue and generalized malaise lasting several days - Nausea, vomiting, and loss of appetite

Serious or Rare Side Effects: - Severe cytokine release syndrome requiring intensive care and vasopressor support - Immune effector cell‑associated neurotoxicity syndrome (ICANS) with severe seizures or cerebral edema - Prolonged cytopenias leading to heightened infection risk and possible transfusion dependence - B‑cell aplasia causing hypogammaglobulinemia and recurrent infections

Before initiating Kymriah, clinicians should observe several precautionary measures to ensure patient safety.

- Patient selection: confirm CD19‑positive disease and meet eligibility criteria for CAR‑T therapy. - Baseline organ function: evaluate cardiac, hepatic and renal parameters before infusion. - Monitoring for CRS: observe vital signs, laboratory markers, and intervene promptly if syndrome develops. - Neurotoxicity surveillance: conduct regular neurologic examinations during the first weeks post‑infusion. - Pregnancy and lactation: avoid use; safety in pregnant or breastfeeding women is not established. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Kymriah can interact with other therapies, requiring careful management.

Major Interactions (Avoid): - Live vaccines: may cause uncontrolled infection due to immunosuppression from CAR‑T therapy. - High‑dose corticosteroids given concurrently: can suppress CAR‑T cell expansion and reduce efficacy. - Additional cellular therapies: may interfere with T‑cell function and increase safety risks.

Moderate Interactions (Monitor Closely): - Antimicrobial prophylaxis agents: adjust dosing as cytopenias may heighten infection susceptibility. - Anticoagulants: monitor bleeding risk when thrombocytopenia occurs after infusion. - Cytokine‑targeting agents (e.g., tocilizumab) used for CRS management: balance therapeutic benefit against infection risk. - Other immunomodulators: observe for additive immune‑related adverse events and possible reduced CAR‑T activity.